The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer
Open accessAbstract
The MHC class I chain-related molecules (MICs) have previously been shown to be induced on most epithelial tumor cells. Engagement of MIC by the activating immune receptor NKG2D triggers NK cells and augments antigen-specific CTL anti-tumor immunity. The MIC-NKG2D system was proposed to participate in epithelial tumor immune surveillance. Paradoxically, studies suggest that tumors may evade MIC-NKG2D-mediated immunity by MIC shedding-induced impairment of effector cell function. Here we demonstrate the first evidence to our knowledge of a significant correlation of MIC shedding and deficiency in NK cell function with the grade of disease in prostate cancer. MIC is widely expressed in prostate carcinoma. The presence of surface target MIC, however, is counteracted by shedding. A significant increase in serum levels of soluble MIC (sMIC) and deficiency in NK cell function was shown in patients with advanced cancer. Finally, the deficiency in NK cell function can be overcome by treatment with IL-2 or IL-15 in vitro. Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D-mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Self-citationRoles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Self-citationRecognition of Stress-Induced MHC Molecules by Intestinal Epithelial γδ T Cells
Groh, V., Steinle, A., Bauer, S., & Spies, T. (1998) · Science · doi:10.1126/science.279.5357.1737 · Cited by 1,142
Self-citationRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R., & Spies, T. (2001) · Nature Immunology · doi:10.1038/85321 · Cited by 951
Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N., & Raulet, D. H. (2000) · Nature Immunology · doi:10.1038/77793 · Cited by 878
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
“Further, soluble MICA (sMICA) has been shown to systemically down-regulate NKG2D, and reduced NKG2D expression on tumour-infiltrating and peripheral blood T and NK cells of tumour patients correlates Oncogene with elevated sMICA sera levels (Groh et al., 2002; Wu et al., 2004).”
BackgroundSelf-citationNKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Effect of NKG2D ligand expression on host immune responses
Champsaur, M., & Lanier, L. L. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00893.x · Cited by 488
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Harvey, C. J., et al. (2018) · Science · doi:10.1126/science.aao0505 · Cited by 459
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 439
Ashiru, O., Boutet, P., Fernández-Messina, L., Agüera-González, S., Skepper, J. N., Valés-Gómez, M., & Reyburn, H. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1688 · Cited by 421
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404
Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments
Taylor, D. D., & Gercel-Taylor, C. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-010-0234-8 · Cited by 383
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
Tumor-Associated MICA Is Shed by ADAM Proteases
Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Stevanovic, S., Rammensee, H.-G., & Steinle, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6768 · Cited by 375
Self-citationLundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., & Wikström, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108925 · Cited by 291
KIR and disease: a model system or system of models?
Khakoo, S. I., & Carrington, M. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00459.x · Cited by 280
Ghiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
Natural killer cells: In health and disease
Mandal, A., & Viswanathan, C. (2015) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2014.11.006 · Cited by 271
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
NKG2D ligands as therapeutic targets.
(2013) · Europe PMC (PubMed Central) · Cited by 218
Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., Poizat, F., Bentobji, M., Azario-Cheillan, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1965 · Cited by 209
Barsoum, I. B., Hamilton, T. K., Li, X., Cotechini, T., Miles, E. A., Siemens, D. R., & Graham, C. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2104 · Cited by 188
“Wu and colleagues reported the shedding of MIC molecules in advanced prostate cancers and that this shedding may be part of a mechanism of escape from immune cytotoxicity (28).”
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Self-citation
Metadata
- Authors
- Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-16
- Volume
- 114
- Issue
- 4
- Pages
- 560-568
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1972814015
- Cited by
- 330
- References
- 42
- FWCI
- 7.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.